| 包装 | 库存 | 价格 | |
|---|---|---|---|
暂无数据 | |||
推荐产品
基本信息
英文别名NCH-51 |
安全信息
存储条件Freezer -20℃ | Symbol  |
Signal WordDanger | Hazard StatementsH318 H413 |
Precautionary StatementsP280 P317 P273 P501 P264+P265 P305+P354+P338 | |
化学和物理性质
产品描述
产品描述
PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM. IC50 value: 1-10 μM (EC50) Target: HDAC in vitro: In cancer cell growth inhibition assay, PTACH shows strong activity. PTACH inhibits various cancer cells with EC50 of 2.3, 9.1, 3.0, 2.6, 1.1, 4.5, 2.4, 5.0, and 4.5 μM for MDA-MB-231 breast cancer, SNB-78 central nervous system, HCT116 colon cancer, NCI-H226 lung cancer, LOX-IMVI melanoma, SK-OV-3 ovarian cancer, RXF-631L renal cancer, St-4 stomach cancer, and DU-145 prostate cancer.
靶点（IC50 & Targe）
HDAC
参考文献
[1]. Suzuki T, et al. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-1032.
